Financial Performance - Revenue for the year ended December 31, 2025, was RMB 1,292.9 million, a decrease of 4.1% compared to RMB 1,348.4 million for the year ended December 31, 2024[3] - Net profit for the year ended December 31, 2025, was RMB 24.1 million, down 33.8% from RMB 36.5 million for the year ended December 31, 2024[5] - Operating profit for the year ended December 31, 2025, was RMB 22.5 million, compared to RMB 27.8 million for the year ended December 31, 2024[7] - The company reported a total comprehensive income of RMB 15.3 million for the year ended December 31, 2025, down from RMB 29.4 million for the year ended December 31, 2024[8] - Basic and diluted earnings per share for the year ended December 31, 2025, were RMB 0.15, compared to RMB 0.23 for the year ended December 31, 2024[8] Assets and Liabilities - Total assets as of December 31, 2025, amounted to RMB 1,055.4 million, down from RMB 1,189.9 million as of December 31, 2024[9] - Current assets as of December 31, 2025, were RMB 947.7 million, compared to RMB 1,086.6 million as of December 31, 2024[9] - Total liabilities for 2025 amount to RMB 396,303,000, while for 2024, it was RMB 469,480,000, indicating a decrease of approximately 15.6%[11] - Current liabilities for 2025 are RMB 382,685,000, compared to RMB 440,902,000 in 2024, reflecting a reduction of about 13.2%[11] - Non-current liabilities total RMB 13,618,000 for 2025, down from RMB 28,578,000 in 2024, showing a decline of approximately 52.4%[11] Revenue Breakdown - B2B sales contributed RMB 656,100 thousand in 2025, up from RMB 649,007 thousand in 2024, while B2C sales decreased to RMB 633,150 thousand from RMB 687,817 thousand[22] - Health products revenue grew significantly by 67.2% year-on-year, reaching RMB 241.8 million, accounting for 18.7% of total revenue[57] - The revenue from adult personal care products decreased by 14.0% to RMB 764.7 million, primarily due to the termination of a strategic partnership with a personal care brand[57] - Revenue from cross-border e-commerce increased by 41.0% to RMB 240.2 million, reflecting a growing market segment[59] Dividends - The board proposed a final dividend of HKD 0.25 per share for the year ended December 31, 2025[6] - The proposed final dividend for the year ended December 31, 2025, is HKD 0.25 per share, totaling HKD 41.5 million (approximately RMB 36.5 million), down from HKD 82.9 million (approximately RMB 75.9 million) in 2024[51] - The company will not declare an interim dividend for the six months ended June 30, 2025, compared to an interim dividend of HKD 0.25 per share for the same period in 2024[50] Corporate Governance - The board of directors consists of three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced governance structure[95] - The audit committee, comprising three independent non-executive directors, is responsible for reviewing the company's financial reporting system and internal controls[100] - The company has adopted the corporate governance code and is committed to maintaining high standards of corporate governance[93] Strategic Focus - The company plans to strategically invest in the health sector, focusing on acquiring external quality brands and enhancing its own brand matrix[90] - The company aims to optimize existing core businesses, innovate products and services, and strengthen digital capabilities to drive high-quality growth[90] - The company is actively optimizing its brand matrix and focusing on high-growth potential business areas to mitigate low-price competition risks[54] Cash Flow and Financing - The net cash used in operating activities was RMB 93.8 million, a significant decline from the previous year, primarily due to increased inventory costs related to brand expansion and extended reimbursement periods for promotional expenses[71] - The net cash generated from investing activities was RMB 14.8 million, mainly from receiving dividends of RMB 15.6 million from joint ventures[71] - The net cash used in financing activities was RMB 53.7 million, primarily due to dividend payments of RMB 75.6 million to shareholders, offset by cash obtained from new borrowings of RMB 21.9 million[72] Market Environment - The macro environment shows a moderate recovery in consumer markets, which the company plans to leverage for sustainable development in 2026[88]

EF001 發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本公告日期，本公司執行董事為王勇先生、沈宇先生及陳偉偉女士；本公司非執行董事為中山國慶先生；而本公司獨立非執行董 事為吳錦華博士、魏航先生及辛洪華女士。 第 2 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 优趣汇控股有限公司 | | 股份代號 | 02177 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月30日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 現行組織章程大綱及細則 UNQ HOLDINGS LIMITED 優趣匯控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2177） 建議修訂 本公告乃由 優趣匯 控股有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則（「上市規則」）第13.51(1)條 作 出。 本公司董事（「董 事」）會（「董事會」））建議對本公司現行第三次經修訂及重列組 織章程大綱及細則（「現行組織章程大綱及細則」）作出若干修訂（「建議修訂」）並 採納本公司第四次經修訂及重列組織章程大綱及細則（「新組織章程大綱及細 則」）。 董 事 會 建 議 修 訂 現 行 組 織 章 程 大 綱 及 細 則，以(i)使 本 公 司 符 合 有 關 混 合 會 議、 電子投票及上市發行人以電子方式發佈公司通訊之最新監管規定及上市規則 的 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 優趣匯控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2177） 變更聯席公司秘書及 授權代表 优 趣 匯 控股有限公司（「本公司」）董事會（「董事會」，連 同 其 附 屬 公 司 統 稱「本 集 團」）謹 此 宣 佈，伍 秀 薇 女 士（「伍女士」）因 工 作 調 動，已 提 出 辭 任 本 公 司 聯 席 公 司秘書（「聯席公司秘書」）及香港聯合交易所有限公司（「聯交所」）證券上市規則 （「上市規則」）第3.05條項下本公司之授權代表（「授權代表」），自2026年3月30日 起 生 效。伍 女 士 已 確 認 與 董 事 會 概 無 分 歧，亦 無 其 他 有 關 其 辭 任 之 事 宜 須 提 請 本 公 司 股 東 或 聯 交 所 注 意。 董 事 會 欣 然 進 一 步 宣 佈，潘 慧 珊 女 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 會 就 本 通 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 UNQ HOLDINGS LIMITED 優趣匯控股有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2177） 董事會會議通告 優趣匯 控股有限公司（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二六年三月三十日（星 期 一）舉 行 董 事 會 會 議，藉 以（其 中 包 括）考慮及批准本公 司及其附屬公司截至二零二五年十二月三十一日止年度的全年業績及其發佈， 並考慮派發末期股息（如 有），及 處 理 其 他 事 項。 承董事會命 優趣匯 控股有限公司 王 勇 主 席 香 港，二 零 二 六 年 三 月 十 七 日 於 本 通 告 日 期，本 公 司 執 行 董 事 為 王 勇 先 生、沈 宇 先 生 及 陳 偉 偉 女 士；本 公 司 非 執 行 董 事 為 中 山 國 慶 先 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 优趣汇控股有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02177 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,800,000,000 | HKD | | 0.0001 HKD | | 380,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 3,800,000,000 | HKD | | 0.0001 HKD | | 380,000 | 本月底法定/註冊股本總額： HKD 380,000 F ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2026年1月31日 | | --- | | 狀態: 新提交 | 致：香港交易及結算所有限公司 公司名稱: 优趣汇控股有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 02177 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 165,894,700 0 165,894,700 增加 / 減少 (-) 0 0 本月底結存 165,894,700 0 165,894,700 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | | --- | | ✔ 已符合適用的公眾持股量要求（見下方） | | 未符合適用的公眾持股量要求（見下方） | | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 优趣汇控股有限公司 呈交日期: 2026年1月6日 本月底法定/註冊股本總額： HKD 380,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02177 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 165,894,700 | | 0 | | 165,894,700 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 165,894,700 | | 0 | | 165,894, ...

Core Viewpoint - The acquisition of 90% stake in One Two Co., Ltd. by Youquhui Holdings for 2.701 billion yen (approximately 135 million HKD) marks a strategic move to establish a second growth curve for the company, enhancing its influence in the health consumption sector and integrating online and offline retail ecosystems [1][2][5]. Group 1: Acquisition Details - Youquhui has completed the acquisition of 90% of One Two Co., Ltd., which operates the Japanese pharmacy chain "あかひげ薬局" [1]. - The acquisition cost was 2.701 billion yen (approximately 135 million HKD), and the brand name and core team of あかひげ薬局 will be retained post-acquisition [1]. - あかひげ薬局 focuses on health management for middle-aged and elderly men, providing personalized health solutions through a one-on-one consultation model [3]. Group 2: Strategic Significance - The acquisition strengthens Youquhui's position in the high-potential health consumption market and provides access to a rare localized overseas brand [2]. - Youquhui aims to leverage the established retail network and expertise of あかひげ薬局 to transition from online operations to a hybrid online and offline retail ecosystem [2][4]. - The integration of Youquhui's digital capabilities with あかひげ薬局's professional services is expected to enhance operational efficiency and market reach [4]. Group 3: Growth Strategy - Youquhui has been actively building its second growth curve, previously launching the Canadian anti-aging health food brand Vanpearl and recruiting international experts to bolster its talent pool [6][7]. - The acquisition of あかひげ薬局 is seen as a natural extension of Youquhui's long-term strategy, enhancing its capabilities in research, brand management, and service delivery [7]. - The company is positioned to potentially engage in further acquisitions in the health consumption sector to strengthen its comprehensive capabilities across research, branding, and multi-channel operations [7][8].

Core Viewpoint - The acquisition of 90% stake in One Two Co., Ltd. by Youquhui Holdings for 2.701 billion yen (approximately 135 million HKD) marks a strategic move to establish a second growth curve for the company, enhancing its influence in the health consumption sector and integrating online and offline retail ecosystems [1][2][5]. Group 1: Acquisition Details - Youquhui has completed the acquisition of 90% of One Two Co., Ltd., which operates the Japanese pharmacy chain "あかひげ薬局" [1]. - The acquisition cost was 2.701 billion yen (approximately 135 million HKD), and the brand name and core team of あかひげ薬局 will be retained post-acquisition [1]. - あかひげ薬局 focuses on health management for middle-aged and elderly men, providing personalized health solutions through a one-on-one consultation model [3]. Group 2: Strategic Significance - The acquisition strengthens Youquhui's position in the high-potential health consumption market and provides access to a rare localized overseas brand [2]. - Youquhui aims to leverage the established retail network and expertise of あかひげ薬局 to transition from online operations to a hybrid online and offline retail model [2][4]. - The collaboration is expected to shorten the incubation period for developing proprietary brands and enhance competitive growth [2]. Group 3: Operational Synergies - Youquhui's extensive experience in the Japanese market and its established operational systems will facilitate the integration of あかひげ薬局 into its business model [4]. - The company plans to innovate service models, expand regional markets, and upgrade technology in collaboration with あかひげ薬局 [4]. - The focus will be on creating a comprehensive ecosystem that combines professional pharmaceutical services with intelligent health management across multiple markets in Asia [4]. Group 4: Growth Trajectory - Youquhui has been actively building its second growth curve, previously launching the Canadian anti-aging health food brand Vanpearl [6][7]. - The acquisition of あかひげ薬局 complements the establishment of a proprietary brand and enhances Youquhui's capabilities in research, brand management, and multi-channel operations [7]. - The company is expected to pursue further acquisitions in the health consumption sector to strengthen its full-chain capabilities [7][8]. Group 5: Market Positioning - The strategic moves by Youquhui are aligned with current market trends, positioning the company favorably amidst a slowing economic environment [8]. - The establishment of a new growth engine beyond its traditional business is anticipated to enhance the company's long-term investment value [8].